Using Citizen Science to organize biomedical knowledge
Using Citizen Science to
organize biomedical
knowledge
Andrew Su, Ph.D.
@andrewsu
asu@scripps.edu
http://sulab.org
March 5, 2015
Future of Genomic Medicine
Slides posted at slideshare.net/andrewsu
The biomedical literature is growing fast…
3
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1983 1988 1993 1998 2003 2008 2013
Number of new PubMed-indexed articles
… but it is very hard to query and compute
5
Imatinib
Crizotinib
Erlotinib
Gefitinib
Sorafenib
Lapatinib
Dasatinib
…
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia
Chronic lymphocytic leukemia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Myeloma
…
AND
8
Doğan and Lu. Proceedings of the 2012 Workshop on BioNLP, 2012, 91-9.
NCBI Disease Corpus
593 PubMed abstracts 12 expert annotators
(2 per document)
6,900 “disease concept” mentions
Question: Can a group of non-scientists
collectively perform concept recognition in
biomedical texts?
9
Experimental design
Task: Identify the “disease concepts” in
the 593 abstracts from the NCBI disease
corpus
– $0.06 per Human Intelligence Task (HIT)
– HIT = annotate one abstract from PubMed
– 15 workers annotate each abstract
11
Comparison to gold standard
12
K = 6
F score = 0.87
• 593 documents
• 15 users / doc
• 9 days
• 145 workers
• $630.96
Precision
Recall
Does Citizen Science scale?
21
1,000,000 articles * 10 AE / article
15,828
volunteers
needed
10,275 AE * 365 days
212 annotators* 28 days
AE = Annotation events
=
Number of annotation
events per year
Number of annotation
events per year
per volunteer
Annotating the relationships
23
This molecule inhibits the growth of a broad
panel of cancer cell lines, and is particularly
efficacious in leukemia cells, including
orthotopic leukemia preclinical models as
well as in ex vivo acute myeloid leukemia
(AML) and chronic lymphocytic leukemia
(CLL) patient tumor samples. Thus, inhibition
of CDK9 may represent an interesting
approach as a cancer therapeutic target
especially in hematologic malignancies.
therapeutic target
subject
predicate
object
GENE
DISEASE
25
Cyrus Afrasiabi
Sebastian Burgstaller
Ramya Gamini
Louis Gioia
Salvatore Loguercio
Adam Mark
Erick Scott
Greg Stupp
Andra Waagmeester
Kevin Xin
Other group members
Contact
http://sulab.org
asu@scripps.edu
@andrewsu
+Andrew Su
Mark2Cure
Ben Good
Max Nanis
Ginger Tsueng
Chunlei Wu
All Mark2Curators!
Funding and Support
BioGPS: GM83924
Gene Wiki: GM089820
BD2K Center of Excellence: GM114833
Icon credits (Noun Project, Wikimedia Commons): Zach VanDeHey, hunotika, Viktorvoigt, Alberto Rojas, Lloyd Humphreys
Matt and Cristina Might
NGLY1 community
Why do I Mark2Cure?
26
I am retired, have a doctorate in
medical humanities, and have two
children with Gaucher disease. I am
just looking for some way to put my
education to use.
My 4 year old daughter Phoebe is
living with and battling rare
disease.
I have Ehlers Danlos Syndrome. I hope to help people
learn about this painful and debilitating disorder, so that
others like me can receive more effective medical care.
Take part in
something that
helps humanity.
I Mark2Cure in memory of
my son Mike who had type 1
diabetes.
Studied biology in
college and I really
miss it!
In memory of my daughter
who had Cystic Fibrosis
To give back